127733-40-8

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE HCL is used as a reactant for the preparation of palladium complexes with chiral pincer ligands. These complexes are of significant interest in the pharmaceutical industry due to their potential applications in catalysis and the development of new drugs with improved selectivity and reactivity.
Used in Chemical Synthesis:
In the field of chemical synthesis, (R)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE HCL serves as a versatile building block for the creation of a wide range of chiral molecules. Its unique structure allows for the development of novel compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Catalyst Development:
(R)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE HCL is used as a key component in the development of chiral catalysts. These catalysts play a crucial role in various chemical reactions, particularly in asymmetric synthesis, where they help to control the stereochemistry of the products, leading to the formation of enantiomerically pure compounds with potential applications in the pharmaceutical and agrochemical industries.

InChI:InChI=1/C10H9F6N.ClH/c1-5(17)6-2-7(9(11,12)13)4-8(3-6)10(14,15)16;/h2-5H,17H2,1H3;1H/t5-;/m1./s1

Upstream product

• 127733-38-4 3,5-bis(trifluoromethyl)acetophenone O-methyloxime 
• 742097-67-2 N-(1-(3,5-bis(trifluoromethyl)phenyl)ethyl)formamide 
• 187085-97-8 (RS)-α-methyl-3,5-bis(trifluoromethyl)benzenemethanamine 
• 225920-05-8 (S)-3,5-bis(trifluoromethyl)-1-phenylethanol 
• 1351520-15-4 (R)-1-bromo-1-[3,5-bis(trifluoromethyl)phenyl]ethane 
• 1370726-04-7 (S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl azide 
• 368-63-8 (R)-[3,5-bis(trifluoromethyl)phenyl]ethanol 
• 1098069-30-7 (E)-1-[3,5-bis(trifluoromethyl)phenyl]ethanone O-benzyloxime 
• 68120-60-5 1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-ol 
• 534613-13-3 (R)-O-acetyl-1-(3,5-bis(trifluoromethyl)phenyl)ethanol 
• 160376-84-1 1-[3,5-bis(trifluoromethyl)phenyl]ethyl bromide 
• 1446706-33-7 1-[3,5-bis(trifluoromethyl)phenyl]ethyl azide 
• 384824-39-9 C₈H₈O₃*C₁₀H₉F₆N 
• 384824-37-7 C₄H₆O₆*C₁₀H₉F₆N 

Downstream Products

• 384824-36-6 C₇H₈O₃S*C₁₀H₉F₆N 
• 384824-39-9 C₈H₈O₃*C₁₀H₉F₆N 
• 1001088-64-7 (S,E)-N-(1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-3-(6-bromopyridin-2-yl)-2-cyanoacrylamide 
• 1355162-92-3 (S)-N-[1-(3,5-bistrifluoromethylphenyl)ethyl]acetamide 

Relevant academic research and scientific papers

Modified Kagan's amide: Synthesis and application as a chiral solvating agent for hydrogen-bonding based chiral discrimination in NMR

A modified Kagan's amide, N-((S)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-3,5-dinitrobenzamide [(S)-2] has been designed, synthesized and screened as a Chiral Solvating Agent (CSA) for discrimination of optically active substrates. The proposed mode of action for recognition of chiral isomers of analytes by CSA is based on hydrogen-bonding. The 1H NMR signals of the two isomers of chiral amides, sulfoxides, α-substituted acids, α-hydroxy ketone, epoxy ketone and N-protected amino acids with (S)-2 were well resolved for practical applications of determination of optical purity. The CSA was also screened for detection of separation of signals in 19F NMR. This journal is

AGENT FOR INHIBITING EXPRESSION OF NPC1L1 AND/OR LIPG MRNA AND AGENT FOR PREVENTING AND/OR TREATING OBESITY

Provided is an agent for treating and/or preventing obesity. An agent for suppressing expression of NPC1L1 (Niemann-Pick disease, type C1, gene-like 1) and/or LIPG (Lipase, endothelial) mRNA, and an agent for preventing and/or treating obesity, each comprising, as an active ingredient, a compound having CETP inhibitory activity, or a salt thereof, or a solvate thereof.

Asymmetric synthesis of nonracemic primary amines via spiroborate-catalyzed reduction of pure (E)- and (Z)-O-benzyloximes: Applications toward the synthesis of calcimimetic agents

Highly enantiopure (1-aryl)- and (1-naphthyl)-1-ethylamines were synthesized by the borane-mediated reduction of single-isomeric (E)- and (Z)-O-benzyloxime ethers using the stable spiroborate ester derived from (S)-diphenyl valinol and ethylene glycol as the chiral catalyst. Primary (R)-arylethylamines were prepared by the reduction of pure (Z)-ethanone oxime ethers in up to 99% ee using 15% of catalyst. Two convenient and facile approaches to the synthesis of new and known calcimimetic analogues employing enantiopure (1-naphthalen-1-yl)ethylamine as chiral precursor are described.

METHOD FOR PRODUCING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE

A method for preparing optically active 1-bromo-1-[3,5-bis(trifluoromethyl)phenyl]ethane having a high optical purity, which comprises the step of brominating optically active 1-[3,5-bis(trifluoromethyl)phenyl]ethanol by using, as a brominating agent, (a) a combination of a phosphorus halide and hydrogen bromide, (b) a combination of 1,2-dibromo-1,1,2,2-tetrachloroethane and an organic phosphorous compound represented by the general formula (I): P(R1)(R2)(R3) (in the formula, R1, R2, and R3 independently represent a C6-10 aryl group, a C6-10 aryloxy group, a C1-10 alkyl group, a C1-10 alkoxyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkoxy group), or (c) a combination ofN-bromosuccinimide and a dialkyl sulfide.

OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME

Substantially optically pure (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid, or a salt thereof, or a solvate thereof, which has actions of reducing amount of PCSK9 protein and increasing amount of LDL receptor.

AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA

The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvate of any of them as an active ingredient: wherein the symbols are the same as those given in the description..

Indanyl-piperazine compounds

A compound selected from those of formula (I): wherein: R3 represents a hydrogen atom, and R1 and R2 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, ?or R1 represents a hydrogen atom, and R2 and R3 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, n represents 1 or 2, —X— represents a group selected from —(CH2)m—O-Ak-, —(CH2)m—NR4-Ak-, —(CO)—NR4-Ak- and —(CH2)m—NR4-(CO)—, ?m represents an integer between 1 and 6 inclusive, Ak represents an optionally substituted alkylene chain, and R4 represents a hydrogen atom or an alkyl group, Ar represents an aryl or heteroaryl group, its enantiomers, diasteroisomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.

Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same

An optically active 1-(fluoro- or trifluoromethyl-substituted phenyl)ethylamine is produced with high optical purity and in an industrially simple and efficient manner by asymmetrically reducing an optically active imine, obtained by dehydration and conde

Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N′- arylthiourea inhibitors of CMV

A series of highly potent thiourea inhibitors of cytomegalovirus (CMV) with improved stability properties was prepared and evaluated. Compound 29 inhibited the virus in cultured HFF cells with IC50 of 0.2nM.

Highly regioselective hydrogenolysis of bis(α-methylbenzyl)amine derivatives affected by the trifluoromethyl substituent on the aromatic ring

(Matrix presented) The highly regioselective hydrogenolysis of bis(α-methylbenzyl)amine derivatives proceeded with influence not from the electronic effect but from the steric effect of the trifluoromethyl substituent on the aromatic ring to provide a practical asymmetric synthesis of trifluoromethyl-substituted α-phenylethylamines.